Compass Pathways at Cantor Healthcare Conference
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The announcement is a routine corporate communication with minimal direct market impact. It may modestly increase visibility for Compass Pathways among investors attending the conference, but no material financial or operational changes are expected.
Compass Pathways plc announced that its management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026, participating in a fireside chat at 3:20pm ET and a panel titled 'PSYCH! Accessing The New Wave of Psychedelics' at 4:30pm ET. The company is developing COMP360, an investigational synthetic psilocybin treatment for treatment-resistant depression and post-traumatic stress disorder, which has received Breakthrough Therapy designation from the United States — Food and Drug Administration and Innovative Licensing and Access Pathway designation in the United Kingdom. The event provides a platform for Compass Pathways to present its clinical programs and engage with investors and industry peers.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard